BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31262889)

  • 1. DL-Methadone as an Enhancer of Chemotherapeutic Drugs in Head and Neck Cancer Cell Lines.
    Landgraf V; Griessmann M; Roller J; Polednik C; Schmidt M
    Anticancer Res; 2019 Jul; 39(7):3633-3639. PubMed ID: 31262889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial Effects of Curcumin with an Anti-Neoplastic Agent on Head and Neck Squamous Cell Carcinoma Through the Regulation of EGFR-ERK1/2 and Apoptotic Signaling Pathways.
    Sivanantham B; Sethuraman S; Krishnan UM
    ACS Comb Sci; 2016 Jan; 18(1):22-35. PubMed ID: 26505786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
    Theile D; Gal Z; Warta R; Rigalli JP; Lahrmann B; Grabe N; Herold-Mende C; Dyckhoff G; Weiss J
    Cancer Biol Ther; 2014 Apr; 15(4):436-42. PubMed ID: 24448417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Notch1 expression affects chemosensitivity of head and neck squamous cell carcinoma to paclitaxel and cisplatin treatment.
    Zhang Z; Zhou Z; Zhang M; Gross N; Gong L; Zhang S; Lei D; Zeng Q; Luo X; Li G; Li X
    Biomed Pharmacother; 2019 Oct; 118():109306. PubMed ID: 31545250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and chemotherapeutic implications of a novel four-gene pyroptosis model in head and neck squamous cell carcinoma.
    Yuan P; Jiang S; Wang Q; Wu Y; Jiang Y; Xu H; Jiang L; Luo X
    PeerJ; 2024; 12():e17296. PubMed ID: 38756442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
    Bu LL; Zhao ZL; Liu JF; Ma SR; Huang CF; Liu B; Zhang WF; Sun ZJ
    Oncotarget; 2015 Dec; 6(39):41944-58. PubMed ID: 26556875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro.
    Rigalli JP; Reuter T; Herold-Mende C; Dyckhoff G; Haefeli WE; Weiss J; Theile D
    Cancer Chemother Pharmacol; 2013 May; 71(5):1335-43. PubMed ID: 23479137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
    Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
    Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
    Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
    Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synergistic cytotoxicity of cisplatin and taxol in killing oral squamous cell carcinoma.
    Huang GC; Liu SY; Lin MH; Kuo YY; Liu YC
    Jpn J Clin Oncol; 2004 Sep; 34(9):499-504. PubMed ID: 15466821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma.
    Theile D; Ketabi-Kiyanvash N; Herold-Mende C; Dyckhoff G; Efferth T; Bertholet V; Haefeli WE; Weiss J
    Head Neck; 2011 Jul; 33(7):959-68. PubMed ID: 20737486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methadone-Not a magic bullet in melanoma therapy.
    Brüggen MC; Mangana J; Irmisch A; French LE; Levesque MP; Cheng PF; Dummer R
    Exp Dermatol; 2018 Jun; 27(6):694-696. PubMed ID: 29577418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ammonium tetrathiomolybdate enhances the antitumor effect of cisplatin via the suppression of ATPase copper transporting beta in head and neck squamous cell carcinoma.
    Ryumon S; Okui T; Kunisada Y; Kishimoto K; Shimo T; Hasegawa K; Ibaragi S; Akiyama K; Thu Ha NT; Monsur Hassan NM; Sasaki A
    Oncol Rep; 2019 Dec; 42(6):2611-2621. PubMed ID: 31638244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.
    Specenier P; Vermorken JB
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):901-915. PubMed ID: 29999437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental study of CF chemotherapy, combined with another one chemotherapeutic drug against head and neck cancer cell lines].
    Tsukuda M; Mochimatsu I; Kokatsu T; Ito K; Furukawa S; Inoue T; Watanabe S; Sawaki S
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):553-6. PubMed ID: 1373052
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting chemotherapy-induced VEGF up-regulation by VEGF antisense oligonucleotides in HNSCC cell lines.
    Riedel F; Götte K; Goessler U; Sadick H; Hörmann K
    Anticancer Res; 2004; 24(4):2179-83. PubMed ID: 15330158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells.
    Ijichi K; Adachi M; Hasegawa Y; Ogawa T; Nakamura H; Kudoh A; Yasui Y; Murakami S; Ishizaki K
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):745-52. PubMed ID: 18075740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
    Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
    Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
    Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
    Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.